Epigral Ltd Plans Explosive Revenue Growth with Specialty Chemicals Focus

Epigral Ltd, a key player in specialty chemicals, targets 20% annual growth, aiming to double its revenue by FY2028. Critical growth drivers include increased demand for derivatives, expanded production capacity, and integrated operations. Revenue projections for FY27 estimate between Rs 3,500 to Rs 3,800 crore.

Epigral Ltd, a specialty chemicals leader, is setting ambitious targets with an expected annual growth rate of 20% and plans to more than double its revenue by the fiscal year 2028. This aggressive growth strategy was confirmed by Chairman and Managing Director, Maulik Patel, speaking over the weekend.

The company's revenue growth is primarily driven by sustained demand for derivative and specialty products, alongside a doubling of production capacity. These elements are crucial catalysts for achieving the company's overarching growth objectives, Patel stated, as mentioned in their exchange filings outlining a 37% revenue jump in the first nine months of FY2024-25 compared to the same period last year.

With significant investment in expanding chemical production capacities and new R&D initiatives, Epigral is poised to strengthen its specialty chemicals business. Analysts from Sunidhi and Emkay forecast revenues to reach Rs 3,500 to Rs 3,800 crore by FY27, with improved EBITDA margins thanks to a comprehensive integration approach.

(With inputs from agencies.)